
Fulcrum Therapeutics FULC
€ 3.36
-0.54%
Fulcrum Therapeutics Gesamtes Eigenkapital | FULC
Gesamtes Eigenkapital Jährlich Fulcrum Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 311 M | 349 M | 243 M | 235 M | 199 M | 212 M | 95.2 M | 87.2 M | -63.7 M | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 349 M | -63.7 M | 185 M |
Gesamtes Eigenkapital Vierteljährlich Fulcrum Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 302 M | 311 M | 333 M | 349 M | 198 M | 214 M | 228 M | 243 M | 257 M | 274 M | 214 M | 235 M | 255 M | 275 M | 275 M | 199 M | 221 M | 161 M | 189 M | 212 M | 231 M | 111 M | 128 M | 95.2 M | 105 M | 122 M | 70.6 M | 87.2 M | 102 M | -112 M | 87.2 M | -63.7 M | -63.7 M | -63.7 M | -39.8 M | -33.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 349 M | -112 M | 159 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
151 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
-27.9 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
10 M | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
315 M | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
57.1 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
41.6 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
6.69 M | - | - | $ 13 M | ||
|
Lyra Therapeutics
LYRA
|
-10.7 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
57 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
125 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-38.9 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
648 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
190 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
212 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
63.9 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
3.24 B | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
7.16 M | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
15.8 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
21.5 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
154 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
27.3 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
98.7 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
57.4 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
928 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-473 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
11.8 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
205 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
8.15 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
46.8 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
156 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
15.1 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
163 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-4.08 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-914 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-8.44 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-45.3 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
6.12 M | - | 31.87 % | $ 1.61 M |